Research Article

You have free access to this content

Discovery and validation of urinary biomarkers for prostate cancer

  1. Dan Theodorescu1,2,3,†,
  2. Eric Schiffer4,†,
  3. Hartwig W. Bauer5,
  4. Friedrich Douwes6,
  5. Frank Eichhorn7,
  6. Reinhard Polley8,
  7. Thomas Schmidt9,
  8. Wolfgang Schöfer10,
  9. Petra Zürbig4,
  10. David M. Good11,
  11. Joshua J. Coon11,12,
  12. Harald Mischak Dr.4,*

Article first published online: 7 MAR 2008

DOI: 10.1002/prca.200780082

Issue

PROTEOMICS - Clinical Applications

PROTEOMICS - Clinical Applications

Volume 2, Issue 4, pages 556–570, No. 4 April 2008

Additional Information

How to Cite

Theodorescu, D., Schiffer, E., Bauer, H. W., Douwes, F., Eichhorn, F., Polley, R., Schmidt, T., Schöfer, W., Zürbig, P., Good, D. M., Coon, J. J. and Mischak, H. (2008), Discovery and validation of urinary biomarkers for prostate cancer. PROTEOMICS - Clinical Applications, 2: 556–570. doi: 10.1002/prca.200780082

Author Information

  1. 1

    Department of Urology, University of Virginia, Charlottesville, VA, USA

  2. 2

    Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA, USA

  3. 3

    Department of Molecular Physiology, University of Virginia, Charlottesville, VA, USA

  4. 4

    Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany

  5. 5

    Ludwig-Maximilian-University Munich, Munich, Germany

  6. 6

    St. George Hospital Bad Aibling, Bad Aibling, Germany

  7. 7

    Urological Office, Bad Reichenhall, Germany

  8. 8

    Urological Office, Urologie am Aegi, Hannover, Germany

  9. 9

    Urological Office, Brackenheim, Germany

  10. 10

    Urological Office, Höchstadt, Germany

  11. 11

    Department of Chemistry, University of Wisconsin-Madison, Madison, WI, USA

  12. 12

    Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, WI, USA

  1. †

    Both authors contributed equally.

*Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Str. 7-9, 30625 Hannover, Germany Fax: +49-511-55474431

Publication History

  1. Issue published online: 3 APR 2008
  2. Article first published online: 7 MAR 2008
  3. Manuscript Received: 12 OCT 2007

Funded by

  • NIH. Grant Number: CA104106
  • Eurotransbio. Grant Number: ETB-2006-016
  • University of Wisconsin-Madison
  • Thermo Fisher
  • National Institutes of Health. Grant Number: 1R01GM080148
  • Biotechnology Training Program. Grant Number: NIH 5T32GM08349

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (528K)

Keywords:

  • Capillary electrophoresis;
  • Diagnosis;
  • Mass spectrometry;
  • Prostate carcinoma;
  • Urine

Abstract

Only 30% of patients with elevated serum prostate specific antigen (PSA) levels who undergo prostate biopsy are diagnosed with prostate cancer (PCa). Novel methods are needed to reduce the number of unnecessary biopsies. We report on the identification and validation of a panel of 12 novel biomarkers for prostate cancer (PCaP), using CE coupled MS. The biomarkers could be defined by comparing first void urine of 51 men with PCa and 35 with negative prostate biopsy. In contrast, midstream urine samples did not allow the identification of discriminatory molecules, suggesting that prostatic fluids may be the source of the defined biomarkers. Consequently, first void urine samples were tested for sufficient amounts of prostatic fluid, using a prostatic fluid indicative panel (“informative” polypeptide panel; IPP). A combination of IPP and PCaP to predict positive prostate biopsy was evaluated in a blinded prospective study. Two hundred thirteen of 264 samples matched the IPP criterion. PCa was detected with 89% sensitivity, 51% specificity. Including age and percent free PSA to the proteomic signatures resulted in 91% sensitivity, 69% specificity.

Get PDF (528K)